- Home
- QNCX
as 11-25-2025 3:42pm EST
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
| Founded: | 2012 | Country: | United States |
| Employees: | 36 | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 139.2M | IPO Year: | 2019 |
| Target Price: | $7.75 | AVG Volume (30 days): | 551.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $2.85 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quince Therapeutics Inc. News
QNCX Breaking Stock News: Dive into QNCX Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Quince Therapeutics to Participate at Investor Events in December 2025
Business Wire
13 days ago
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Business Wire
15 days ago
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Business Wire
2 months ago
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
Business Wire
2 months ago
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
Business Wire
5 months ago
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
Business Wire
5 months ago
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
Simply Wall St.
5 months ago
June 2025's Promising Penny Stocks For Savvy Investors
Compare QNCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNCX Quince Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.